Proteomics

Dataset Information

0

Sirt2 inhibition reprograms T cell metabolism for optimal anti-tumor immunity: Sirt2 Interacting Proteins


ABSTRACT: Growing evidence indicates that metabolism is a key driver of T cell functions. A switch from oxidative phosphorylation to aerobic glycolysis is a hallmark of T cell activation and is required to meet metabolic demands of proliferation and effector functions. However, the mechanisms underlying the metabolic switch in T cells remain unclear. Here, we identify Sirt2 as a crucial immune checkpoint coordinating metabolic and functional fitness of T cells. Sirt2 is induced upon T cell activation and increases in late maturation stages. Sirt2 negatively regulates glycolysis by targeting key glycolytic enzymes. Remarkably, Sirt2 knockout T cells exhibit profound upregulation of aerobic glycolysis with enhanced proliferation and effector function and thus effectively reject tumor challenge in vivo. Furthermore, pharmacologic inhibition of Sirt2 in human tumor infiltrating lymphocytes demonstrated a similar phenotype. Taken together, our results demonstrate Sirt2 as an actionable target to reprogram T cell metabolism to augment immunotherapy.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Spleen, T Cell

SUBMITTER: John Koomen  

LAB HEAD: Sungjune Kim, MD

PROVIDER: PXD012811 | Pride | 2020-06-15

REPOSITORIES: Pride

altmetric image

Publications


Dysregulated metabolism is a key driver of maladaptive tumor-reactive T lymphocytes within the tumor microenvironment. Actionable targets that rescue the effector activity of antitumor T cells remain elusive. Here, we report that the Sirtuin-2 (Sirt2) NAD<sup>+</sup>-dependent deacetylase inhibits T cell metabolism and impairs T cell effector functions. Remarkably, upregulation of Sirt2 in human tumor-infiltrating lymphocytes (TILs) negatively correlates with response to TIL therapy in advanced  ...[more]

Similar Datasets

2020-07-03 | PXD020150 | Pride
2020-06-15 | PXD012796 | Pride
2020-09-16 | GSE151421 | GEO
2023-12-05 | PXD045456 | Pride
2020-06-16 | PXD019763 | Pride
2020-02-20 | PXD011523 | Pride
2018-10-26 | PXD006036 | Pride
2015-12-31 | GSE66033 | GEO
2024-07-19 | MSV000095391 | MassIVE
2023-04-08 | GSE229161 | GEO